T2 Biosystems Stock Price, News & Analysis (NASDAQ:TTOO)

$2.83
-0.04 (-1.39 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$2.67
Now: $2.83
$2.87
50-Day Range
$0.58
MA: $1.35
$2.94
52-Week Range
$0.52
Now: $2.83
$7.70
Volume1.20 million shs
Average Volume2.74 million shs
Market Capitalization$126.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTOO
CUSIPN/A
Phone781-761-4646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.50 million
Book Value$0.26 per share

Profitability

Net Income$-51,150,000.00
Net Margins-722.70%

Miscellaneous

Employees153
Market Cap$126.05 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) issued its earnings results on Tuesday, July, 30th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.03. The medical equipment provider earned $1.80 million during the quarter, compared to the consensus estimate of $1.95 million. T2 Biosystems had a negative return on equity of 1,263.94% and a negative net margin of 722.70%. T2 Biosystems's revenue was down 53.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.32) earnings per share. View T2 Biosystems' Earnings History.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for T2 Biosystems.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.7-9.6 million, compared to the consensus revenue estimate of $19.37 million.

What price target have analysts set for TTOO?

8 brokers have issued 12-month target prices for T2 Biosystems' stock. Their predictions range from $0.40 to $10.00. On average, they expect T2 Biosystems' share price to reach $5.6125 in the next year. This suggests a possible upside of 98.3% from the stock's current price. View Analyst Price Targets for T2 Biosystems.

What is the consensus analysts' recommendation for T2 Biosystems?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:
  • 1. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)
  • 2. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (8/1/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019)
  • 4. Canaccord Genuity analysts commented, "We’d like to provide our view and counter the key points made in the report: Point 1 – News of T2’s recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease. Our response – This is true, but it’s still a positive. T2 just started its dialogue with the FDA on its T2Resistance panel, thus FDA has not reviewed data from T2. We believe that breakthrough device designation will (1) add more resources by the FDA on this device and (2) likely provide a speedier review process and ultimately FDA approval." (3/5/2019)

Has T2 Biosystems been receiving favorable news coverage?

Media headlines about TTOO stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. T2 Biosystems earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for T2 Biosystems.

Who are some of T2 Biosystems' key competitors?

What other stocks do shareholders of T2 Biosystems own?

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the folowing people:
  • Mr. John P. McDonough, CEO, Pres & Director (Age 59)
  • Prof. Michael J. Cima, Co-Founder & Director (Age 59)
  • Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
  • Dr. Tyler E. Jacks, Co-Founder (Age 58)
  • Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Morgan Stanley (3.45%), Vanguard Group Inc. (3.12%), BlackRock Inc. (2.32%), Senvest Management LLC (1.99%), Ardsley Advisory Partners LP (1.96%) and JPMorgan Chase & Co. (1.65%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, BlackRock Inc., Morgan Stanley, Bank of New York Mellon Corp, Wells Fargo & Company MN and Northern Trust Corp. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Jane Street Group LLC, Paloma Partners Management Co, Ardsley Advisory Partners LP, A.R.T. Advisors LLC, Tower Research Capital LLC TRC and Private Advisor Group LLC. View Insider Buying and Selling for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $2.83.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $126.05 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is http://www.t2biosystems.com/.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]


MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Featured Article: Commodities

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel